Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2009

Open Access 01-12-2009 | Research

Hepatitis B and C in dialysis units in Kosova

Authors: Skender Telaku, Hajrullah Fejza, Ymer Elezi, Teuta Bicaj

Published in: Virology Journal | Issue 1/2009

Login to get access

Abstract

Background

Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are important causes of morbidity and mortality of hemodialysis (HD) patients. This study aimed to investigate the epidemiological and clinical features of HCV and HBV infections in six different HD units in Kosova.
Five hundred and eighty-three end-stage kidney disease (ESKD) patients on maintenance HD from six HD centers in Kosova (358 female, 225 male, mean age 54,8 years (16–66) were included in this study. Data from databank of the National Blood Bank in Prishtina, as well as the data from the databank of the Transfusion Centers in Regional hospitals in Prizren, Peja, Gjilan, Mitrovica and Gjakova were taken in this study. Clinical data such as age, sex, HBsAg and anti-HCV antibody and primary causes of ESKD were examined.
Serological markers for HBV and HCV were determined with immunoenzymatic assay (ELISA).

Results

The T-test and x2 test were used to analyze the significance of the results. Among our HD patients HBsAg and anti-HCV antibody prevalence rate was 12%, respectively 43%. Chronic nephritis was a more frequent cause of ESKD among our HD patients. With unknown etiology were 23, 5% from them.

Conclusion

HBV and HCV prevalence in our HD patients is still high. These data emphasize the need for stricter adherence to infection control, barrier precaution and preventive behaviors with all patients.
Appendix
Available only for authorised users
Literature
1.
Meyers CM, Seef LB, Stehman-Breen CO, Hoofnagle JH: Hepatitis C and renal disease: an update. Am J Kidney Dis 2003,42(4):631-657. 10.1016/S0272-6386(03)00828-XCrossRefPubMed
2.
Fabrizi F, de Vecchi AF, Como G, Lunghi G, Martin P: De novo HCV infection among dialysis patients: a prospective study by HCV core antigen ELISA assay. Aliment Pharmacol Ther 2005,21(7):861-869. 10.1111/j.1365-2036.2005.02416.xCrossRefPubMed
3.
Wright TL, Pereira BJG: Hepatitis C virus: a threat without a cure to the patient with ESRD. Semin Dial 1997,10(5):241-247. 10.1111/j.1525-139X.1997.tb00502.xCrossRef
4.
Oesterreicher C, Muller C: HBV and HCV genome in peripheral blood mononuclear cells in patients undergoing chronic hemodialysis. Kidney international 1995, 48: 1967-1971. 10.1038/ki.1995.498CrossRefPubMed
5.
Fabrizi F, Messa P, Martin P: Hepatitis B virus infection and the dialysis patient. Semin Dial 2008,21(5):440-446. 10.1111/j.1525-139X.2008.00437.xCrossRefPubMed
6.
Niu MT, Coleman PJ, Alter MJ: Multicenter study of hepatitis C virus infection in chronic hemodialysis patients and hemodialysis staff members. Am J Kidney Dis 1993,22(4):568-573.CrossRefPubMed
7.
Telaku S, Zekaj S, Avdijaj Xh, Elezi Y, Kuqi Xh, Zylfiu B, Rudhani I, Hasanxhekaj V, Fejza H: Prevalence of hepatitis B and C infection in dialysis patient in Kosova. The Turkish Journal of Gastroenterology 2003,14(Suppl 1):106.
8.
Tokars JI, Finelli L, Alter MJ, Arduino MJ: National surveillance of dialysis-associated diseases in the United States 2001. Semin Dial 2004,17(4):310-319. 10.1111/j.0894-0959.2004.17339.xCrossRefPubMed
9.
Kes P, Slavicek J, Jankovic N: Prevention and treatment of hepatitis B in patients on hemodialysis and vaccination of hemodialysis health personnel against hepatitis B. Acta Med Croatica 2005,59(5):479-482.PubMed
10.
Oguchi H, Miyasaka M, Tokunaga S: Hepatitis virus infection (HBV and HCV) in eleven Japanese hemodialysis units. Clin Nephrol 1992,38(1):36-43.PubMed
11.
Boulaajaj K, Elomari Y, Elmaliki B: Prevalence of hepatitis C, hepatitis B and HIV infection among haemodialysis patients in Ibn-Rochd university hospital, Casablanca. Nephrol Ther 2005,1(5):274-284.CrossRefPubMed
12.
Taremi M, Khoshbaten M, Gachkar L, EhsaniArdakani M, Zali M: Hepatitis E virus infection in hemodialysis patients: A seroepidemiological survey in Iran. BMC Infect Dis 2005,5(1):36-38. 10.1186/1471-2334-5-36PubMedCentralCrossRefPubMed
13.
Munter H, Yousef A: Hepatitis B infection among Patients Receiving Chronic Hemodialysis at Royal Medical Services in Jordan. Saudi J Kidney Dis Transpl 2008,19(2):260-267.
14.
Otedo AE, Mc'Ligeyo SO, Okoth FA: Seroprevalence of hepatitis B and C in maintenance dialysis in a public hospital in a developing country. S Afr Med J 2003,93(5):380-384.PubMed
15.
Khan LA, Khan SA: Prevalence of Hepatitis B and C markers in patients on maintenance hemodialysis in Najran. Saudi Med J 2001,22(7):641-642.PubMed
16.
Leung CB, Ho YW, Chau KF, Choy BY, Tsang WK, Lui SF: Renal replacement therapy for chronic hepatitis B carrier: A subgroup analysis from the Hong Kong Renal Registry 1995–1999. Hong Kong J Nephrol 2000, 2: 104-109.CrossRef
17.
Chattopadhyay S, Rao S, Das BC: Prevalence of transfusion-transmitted virus infection in patients on maintenance hemodialysis from New Delhi, India. Hemodial Int 2005,9(4):362-366. 10.1111/j.1542-4758.2005.01154.xCrossRefPubMed
18.
Chen KS, Lo SK, Lee N, Leu ML, Huang CC, Fang KM: Superinfection with hepatitis C virus in hemodialysis patients with hepatitis B surface antigenemia: Its prevalence and clinical significance in Taiwan. Nephron 1996,73(2):158-164. 10.1159/000189033CrossRefPubMed
19.
Covic A, Iancu L, Apetrei C: Hepatitis virus infection in haemodialysis patients from Moldavia. Nephrol Dial Transplant 1999,14(1):40-45. 10.1093/ndt/14.1.40CrossRefPubMed
20.
Siagris D, Christofidou M, Triga K: Occult hepatitis B virus infection in hemodialysis patients with chronic HCV infection. J Nephrol 2006,19(3):327-333.PubMed
21.
Loza Munarriz C, Depaz Dolores M, Jara M: Rate of serological markers of hepatitis B and C viruses in first-time users of the hemodialysis program at Hospital Nacional Cayetano Heredia (HNCH). Rev Gastroenterol Peru 2005,25(4):320-327.PubMed
22.
Yakaryilmaz F, Gurbuz OA, Guliter S: Prevalence of occult hepatitis B and hepatitis C virus infections in Turkish hemodialysis patients. Ren Fail 2006,28(8):729-735. 10.1080/08860220600925602CrossRefPubMed
23.
Ferreira RC, Teles SA, Dias MA: Hepatitis B virus infection profile in hemodialysis patients in Central Brazil: Prevalence, risk factors and genotypes. Mem Inst Oswaldo Cruz 2006,101(6):689-692. 10.1590/S0074-02762006000600019CrossRefPubMed
24.
Fejza H, Telaku S: Prevalence of HBV and HCV among blood donors in Kosova. Virol J 2009, 13: 6-21.
25.
Chironna M, Germinario C, Lopalco PL, Carrozini F, Quatro M: Prevalence of hepatitis virus infections in Kosovar refugees. Int J Infect Dis 2001,5(4):209-213. 10.1016/S1201-9712(01)90073-6CrossRefPubMed
26.
Jadoul M, Cornu C, van Ypersele de Strihou C: Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian Multicenter Study. The Universitaires Cliniques St-Luc (UCL) Collaborative Group. Kidney Int 1998, 53: 1022-1025. 10.1111/j.1523-1755.1998.00823.xCrossRefPubMed
27.
Buturović-Ponikvar J: Renal replacement therapy in Slovenia: annual report 2001. Nephrol Dial Transplant 2003,18(Suppl 5):v53-v55. 10.1093/ndt/gfg1048CrossRefPubMed
28.
Diouf ML, Diouf B, Niang A, Ka EH, Pouye A, Seck A, Raphenon G, Moreira-Diop T: Prevalence of hepatitis B and C viruses in a chronic hemodialysis center in Dakar. Dakar Med 2000, 45: 1-4.PubMed
29.
Ahmetagić S, Muminhodzić K, Cickusić E, Stojić V, Petrović J, Tihić N: Hepatitis C infection in risk groups. Bosn J Basic Med Sci 2006, 6: 13-17.PubMed
30.
Jadoul M, Poignet JL, Geddes C, Locatelli F, Medin C, Krajewska M, Barril G, Scheuermann E, Sonkodi S, Goubau P: The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis. Nephrol Dial Transplant 2004, 19: 904-909. 10.1093/ndt/gfh012CrossRefPubMed
31.
Salama G, Rostaing L, Sandres K, Izopet J: Hepatitis C virus infection in French hemodialysis units: a multicenter study. J Med Virol 2000, 61: 44-51. 10.1002/(SICI)1096-9071(200005)61:1<44::AID-JMV7>3.0.CO;2-JCrossRefPubMed
32.
Hinrichsen H, Leimenstoll G, Stegen G, Schrader H, Fölsch UR, Schmidt WE: Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients. Gut 2002, 51: 429-433. 10.1136/gut.51.3.429PubMedCentralCrossRefPubMed
33.
Rigopoulou EI, Stefanidis I, Liaskos C, Zervou EK, Rizos C, Mina P, Zachou K, Syrganis C, Patsidis E, Kyriakopoulos G, Sdrakas L, Tsianas N, Dalekos GN: HCV-RNA qualitative assay based on transcription mediated amplification improves the detection of hepatitis C virus infection in patients on hemodialysis: results from five hemodialysis units in central Greece. J Clin Virol 2005, 34: 81-85. 10.1016/j.jcv.2005.05.007CrossRefPubMed
34.
Lombardi M, Cerrai T, Geatti S, Negroni S, Pertusini L, Pegoraro M, Di Lullo G: Results of a national epidemiological investigation of HCV infection in dialysis patients. EDTNA ERCA J 1999, 25: 38-42.CrossRefPubMed
35.
Covic A, Iancu L, Apetrei C, Scripcaru D, Volovat C, Mititiuc I, Covic M: Hepatitis virus infection in haemodialysis patients from Moldavia. Nephrol Dial Transplant 1999, 14: 40-45. 10.1093/ndt/14.1.40CrossRefPubMed
36.
Schneeberger PM, Keur I, van Loon AM, Mortier D, de Coul KO, van Haperen AV, Sanna R, van Der Heijden TG, van Den Hoven H, van Hamersvelt HW, Quint W, van Doorn LJ: The prevalence and incidence of hepatitis C virus nfections among dialysis patients in the Netherlands: a nationwide prospective study. J Infect Dis 2000, 182: 1291-1299. 10.1086/315869CrossRefPubMed
37.
Almroth G, Ekermo B, Månsson AS, Svensson G, Widell A: Detection and prevention of hepatitis C in dialysis patients and renal transplant recipients. A long-term follow up (1989–January 1997). J Intern Med 2002, 251: 119-128. 10.1046/j.1365-2796.2002.00938.xCrossRefPubMed
38.
Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, Miller LG, Daar ES, Gjertson DW, Kopple JD, Greenland S: Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol 2007, 18: 1584-1593. 10.1681/ASN.2006070736CrossRefPubMed
39.
Wreghitt TG: Blood-borne virus infections in dialysis units – a review. Rev Med Virol 1999, 9: 101-109. 10.1002/(SICI)1099-1654(199904/06)9:2<101::AID-RMV234>3.0.CO;2-UCrossRefPubMed
40.
Daw MA, Elkaber MA, Drah AM, Werfalli MM, Mihat AA, Siala IM: Prevalence of hepatitis C virus antibodies among different populations of relative and attributable risk. Saudi Med J 2002, 23: 1356-1360.PubMed
41.
El-Amin HH, Osman EM, Mekki MO, Abderlraheem MB, Ismail MO, Yousif ME, Abass A, Elhaj HS, Ammar HK: Hepatitis C virus infection in hemodialysis patients in Sudan:Two centers report. Saudi J Kidney Dis Transpl. 2007,18(1):101-106.PubMed
42.
Bouzgarrou N, Fodha I, Othman SB, Achour A, Grattard F, Trabelsi A, Pozzetto B: Evaluation of a total core antigen assay for the diagnosis of hepatitis C virus infection in hemodialysis patients. J Med Virol 2005, 77: 502-508. 10.1002/jmv.20485CrossRefPubMed
43.
Lopes EP, Gouveia EC, Albuquerque AC, Sette LH, Mello LA, Moreira RC, Coelho MR: Determination of the cutoff value of serum alanine aminotransferase in patients undergoing hemodialysis, to identify biochemical activity in patients with hepatitis C viremia. J Clin Virol 2006, 35: 298-302. 10.1016/j.jcv.2005.09.010CrossRefPubMed
44.
Méndez-Sánchez N, Motola-Kuba D, Chavez-Tapia NC, Bahena J, Correa-Rotter R, Uribe M: Prevalence of hepatitis C virus infection among hemodialysis patients at a tertiary care hospital in Mexico City, Mexico. J Clin Microbiol 2004, 42: 4321-4322. 10.1128/JCM.42.9.4321-4322.2004PubMedCentralCrossRefPubMed
45.
Sanchez JL, Sjogren MH, Callahan JD, Watts DM, Lucas C, Abdel-Hamid M, Constantine NT, Hyams KC, Hinostroza S, Figueroa-Barrios R, Cuthie JC: Hepatitis C in Peru: risk factors for infection, potential iatrogenic transmission, and genotype distribution. Am J Trop Med Hyg 2000, 63: 242-248.PubMed
46.
López-Navedo PJ, Lebrón-Rivera R, González-Trápaga J, Weber-Acevedo J, Lefevre-Ramos E, Flores-de Hostos E, Jaume-Anselmi F, Ramírez-Rivera J: Prevalence of hepatitis C virus infection at three hemodialysis units in the western region of Puerto Rico. Bol Asoc Med P R 1999, 91: 100-102.PubMed
47.
Alavian SM, Einollahi B, Hajarizadeh B, Bakhtiari S, Nafar M, Ahrabi SS: Prevalence of hepatitis C virus infection and related risk factors among Iranian haemodialysis patients. Nephrology (Carlton) 2003, 8: 256-260. 10.1046/j.1440-1797.2003.00166.xCrossRef
Metadata
Title
Hepatitis B and C in dialysis units in Kosova
Authors
Skender Telaku
Hajrullah Fejza
Ymer Elezi
Teuta Bicaj
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2009
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-6-72

Other articles of this Issue 1/2009

Virology Journal 1/2009 Go to the issue

Research

Torque Teno Virus (TTV) distribution in healthy Russian population

Research

Measles Resurgence Associated with Continued Circulation of Genotype H1 Viruses in China, 2005

Research

Characterisation of a GII-4 norovirus variant-specific surface-exposed site involved in antibody binding

Short report

Conserved retinoblastoma protein-binding motif in human cytomegalovirus UL97 kinase minimally impacts viral replication but affects susceptibility to maribavir

Research

Evidence of HIV-1 adaptation to host HLA alleles following chimp-to-human transmission

Research

Induction of cell-cell fusion by ectromelia virus is not inhibited by its fusion inhibitory complex
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits